Please ensure Javascript is enabled for purposes of website accessibility

AbbVie Headed to FDA, Clash With Gilead Set

By Brian Orelli, PhD - Jan 31, 2014 at 6:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

AbbVie and Enanta Pharmaceuticals' hepatitis C drug cocktail is much better than older medications from Merck and Vertex Pharmaceuticals and comparable to Gilead Sciences' new cocktail.

AbbVie (ABBV 0.03%) has finished up its phase 3 clinical-trial program for its all-oral hepatitis C drug cocktail. There were six clinical trials in total, testing the drugs in different patient populations in many cases with and without generic ribavirin.

All the treatment regimens produced sustained virologic responses -- essentially a cure -- in the 90 percents, sans one treatment arm where all 91 patients were cured.

Three years ago, the best a patient infected with genotype 1 hepatitis C could hope for was a 50% chance of clearing the virus. Approval of Vertex Pharmaceuticals'  Incivek and Merck's Victrelis in 2011 raised the cure rate near 80%, but patients still have to take peginterferon, an injected drug that causes flu-like symptoms, for 24-48 weeks.

AbbVie's drugs only have to be taken for 12 weeks in most cases and don't require peginterferon. The data is good news for Enanta Pharmaceuticals (ENTA -2.62%), which helped develop ABT-450, one of the components of the cocktail. Enanta is due double-digit royalties on sales of the drug.

Not the only player in town
Abbvie said it's shooting for submitting its marketing application for the cocktail early in the second quarter, but it won't be the first all-oral cocktail if Gilead Sciences (GILD 0.47%) sticks to its guidance of submitting to the FDA in the first quarter.

We could make comparisons between trials run by the two companies on patients with the same genotypes to see which has higher cure rates, but with most above 95%, the difference isn't likely to be statistically meaningful. Most doctors won't choose between AbbVie's or Gilead's regimen based on a percentage point or two difference in the clinical trial efficacy results.

The earlier filing could give Gilead Sciences a bit of a head start, although it may not have much of one. There's only one day between the end of the first quarter and the start of the second quarter after all. But Gilead already has an indirect head start. One of the components of Gilead's cocktail, Sovaldi, was recently approved for use in combination with peginterferon in genotype 1 patients. Doctors' familiarity with Sovaldi and Gilead's sales reps could give the biotech a leg up.

The choice between the two cocktails could come down to convenience. Gilead's cocktail requires fewer pills, which on the surface doesn't seem like much. As long as patients are taking their medications on the correct schedule it doesn't really matter, but doctors may feel that fewer pills will result in better compliance, which is a really big deal for antiviral medications. If patients don't take all their medication and the virus is knocked down but not out, it can give the virus time to mutate in a way that makes it resistant to the medications.

The deciding factor may come down to price, especially as insurers get involved. If one of the companies is willing to substantially undercut the other, insurers may require that cocktail be used first. Given the high cure rates, that wouldn't leave many scraps for the other company.

If it comes down to price, launching second could give AbbVie a huge advantage.

Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$61.89 (0.47%) $0.29
AbbVie Inc. Stock Quote
AbbVie Inc.
$140.38 (0.03%) $0.04
Enanta Pharmaceuticals, Inc. Stock Quote
Enanta Pharmaceuticals, Inc.
$69.40 (-2.62%) $-1.87

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.